IP Library Granted Patent US 10,800,755
Granted Patent B2
US 10,800,755 · App. 16/827,981 · Granted Oct 13, 2020

2,6-disubstituted pyridine derivative

Inventors: Hidefumi Yoshinaga (Osaka, JP); Hiro Uemachi (Uji, JP); Tomomi Ohno (Toyonaka, JP); Jeremy Besnard (Dundee, GB)
Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.
C07D401/04A61P25/22C07D405/14A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,800,755
App. No.
16/827,981
Granted
Oct 13, 2020
Kind
B2
Abstract

The present invention relates to a pyridine derivative of formula (1) wherein R 1 is optionally-substituted C 1-6 alkyl, optionally-substituted C 3-10 cycloalkyl, or optionally-substituted 5- to 10-membered saturated or partially-unsaturated heterocyclyl; R 2 is halogen atom, cyano, C 1-6 alkyl which may be optionally substituted with 1 to 3 the same or different halogen atoms, C 1-6 alkoxy which may be optionally substituted with 1 to 3 the same or different halogen atoms, or amino which may be optionally substituted with 1 to 2 the same or different C 1-6 alkyl; and the bind with broken line is single or double bond, or a pharmaceutically acceptable salt thereof, which is useful as a medicament for treating symptoms in anxiety-related disorder.

Claims (8)

1. A compound selected from the group consisting of:

4,4-difluoro-N-(2-{4-[6-(trifluoromethyl)pyridin-2-yl]piperidin-1-yl}ethyl)cyclohexane-carboxamide,

N-{2-[4-(6-methylpyridin-2-yl)piperidin-1-yl]ethyl}-tetrahydro-2H-pyran-4-carboxamide, and

N-(2-{4-[6-(trifluoromethyl)pyridin-2-yl]piperidin-1-yl}ethyl)-tetrahydro-2H-pyran-4-carboxamide,

or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 , which is 4,4-difluoro-N-(2-{4-[6-(trifluoromethyl)pyridin-2-yl]piperidin-1-yl}ethyl)cyclohexane-carboxamide, or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 1 , which is N-{2-[4-(6-methylpyridin-2-yl)piperidin-1-yl]ethyl}-tetrahydro-2H-pyran-4-carboxamide, or a pharmaceutically acceptable salt thereof.

4. The compound according to claim 1 , which is N-(2-{4-[6-(trifluoromethyl)pyridin-2-yl]piperidin-1-yl}ethyl)-tetrahydro-2H-pyran-4-carboxamide, or a pharmaceutically acceptable salt thereof.

Assignments (1)
CHANGE OF NAME Recorded Nov 21, 2022
From: SUMITOMO DAINIPPON PHARMA CO., LTD.
To: SUMITOMO PHARMA CO., LTD.
Reel/Frame 061972/0730 →
Priority Claims (1)
JP 2017-046904 · Mar 13, 2017 · national
Continuity (2)
Continuation 16487936
Related Publication 20200239432A1 · Jul 30, 2020